Aldeyra Therapeutics (ALDX) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kalaris Therapeutics (KLRS) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 62.1% versus a loss of 83.1%. Over five years, ALDX leads with a -88.6% price change compared with -99.5% for KLRS. Kalaris Therapeutics is the larger company by market cap ($59.3 million vs $56.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | KLRS |
|---|---|---|
| Share price | $0.9395 | $2.49 |
| Market cap | $56.68M | $59.27M |
| 1-day change | -0.87% | -0.40% |
| YTD return | -81.70% | -70.38% |
| 1-year return | -83.14% | -62.06% |
| 5-year return | -88.64% | -99.51% |
| EPS (TTM) | $-0.38 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $11.88 |
| 52-week low | $0.862 | $2.35 |
| Distance from 52-week high | -84.16% | -79.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +602.50% | +651.41% |
| Average volume | 1.18M | 252.88K |
| Shares outstanding | 60.33M | 23.80M |
| Employees | 6 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KLRS has outperformed ALDX by 21.1 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
ALDX vs KLRS FAQ
Which is bigger, Aldeyra Therapeutics or Kalaris Therapeutics?
Kalaris Therapeutics (KLRS) is larger, with a market capitalization of $59.27M compared with $56.68M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or KLRS?
KLRS returned -62.06% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Kalaris Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aldeyra Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Kalaris Therapeutics.